DeepHealth Unveils Industry’s Most Comprehensive Portfolio of Native Clinical AI Solutions at ECR 2026 

Rhea-AI Summary

DeepHealth (NASDAQ: RDNT) unveiled at ECR 2026 a cloud-first, integrated portfolio of native clinical AI solutions across MR, CT, X-ray, mammography and ultrasound, plus the acquisition of Gleamer to expand musculoskeletal and X-ray capabilities.

Key validated results include a 21% breast cancer detection increase across 579,000 women, 92% sensitivity for hippocampal atrophy, deployment across >200 RadNet sites with >94% AI measurement acceptance, and AI Studio aggregating >140 algorithms from 75 partners.

Positive

• Acquisition of Gleamer expands musculoskeletal and X-ray portfolio
• Breast detection +21% across 579,000 women
• Neuro Suite 92% sensitivity for hippocampal atrophy
• Deployment at >200 RadNet sites with 94% AI acceptance
• AI Studio aggregates 140+ algorithms from 75 partners

Negative

• None.

Key Figures

Breast cancer detection gain: 21% increase Study population: 579,000 women Risk model accuracy: 2x greater accuracy +5 more

8 metrics

Breast cancer detection gain 21% increase Breast Suite applications in Nature Health study

Study population 579,000 women Real-world Nature Health breast cancer screening study

Risk model accuracy 2x greater accuracy Breast Suite AI risk assessment vs traditional risk models

Neuro Suite sensitivity 92% sensitivity Early identification of hippocampal atrophy in cognitive disorders

RadNet deployment sites more than 200 sites Thyroid Suite deployment across RadNet locations

AI measurement acceptance greater than 94% Thyroid AI measurements accepted without correction by radiologists

Scan time reduction up to 30% Reduction in thyroid ultrasound scan slot time

AI algorithms more than 140 algorithms AI Studio platform from over 75 ecosystem partners

Market Reality Check

Price: $72.58 Vol: Volume 1,218,524 is 1.42x...

normal vol

$72.58 Last Close

Volume Volume 1,218,524 is 1.42x the 20-day average of 855,178, indicating elevated trading interest ahead of/around this AI showcase. normal

Technical Shares at 72.58 trade above the 200-day MA of 69.08, but remain 15.45% below the 52-week high of 85.84, suggesting a pullback from recent highs.

Peers on Argus

RDNT fell 3.51% while key diagnostics peers like GH (+3.56%), RVTY (+3.62%), WGS...

1 Down

RDNT fell 3.51% while key diagnostics peers like GH (+3.56%), RVTY (+3.62%), WGS (+7.01%), SHC (+1.23%) and CRL (+1.02%) posted gains, pointing to stock-specific pressure rather than a sector-wide move.

Previous AI Reports

5 past events · Latest: Nov 30 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 30	AI portfolio expansion	Positive	-3.4%	Unveiled expanded imaging informatics and clinical AI suite at RSNA 2025.
Nov 17	Clinical AI study	Positive	+2.8%	Nature Health study showed higher AI breast cancer detection and predictive value.
Nov 12	AI partnership deal	Positive	-1.3%	Expanded GE HealthCare collaboration to scale AI imaging and remote scanning.
Jul 09	AI screening adoption	Positive	+4.2%	Southern California medical groups added AI breast detection program to benefits.
Feb 26	ECR AI launch	Positive	-0.6%	Introduced new AI radiology and population screening tools at ECR 2025.

Pattern Detected

AI-related announcements have produced mixed share reactions, with more instances of short-term negative or muted moves than clear rallies.

Recent Company History

Over the past year, RadNet’s DeepHealth division has repeatedly highlighted advances in AI-powered imaging. At ECR 2025 and RSNA 2025, the company unveiled and expanded integrated AI suites across breast, lung, prostate, thyroid and neuro imaging, supported by real-world data such as a 21.6% boost in breast cancer detection and reduced exam times. Strategic collaborations and payer adoption broadened deployment across hundreds of sites. Today’s ECR 2026 portfolio expansion and Gleamer integration build directly on that progression in clinical breadth and scale.

Historical Comparison

+0.3% avg move · Across 5 prior AI-focused announcements, RDNT’s average move was 0.33% with mixed direction. Today’s...

AI

+0.3%

Average Historical Move AI

Across 5 prior AI-focused announcements, RDNT’s average move was 0.33% with mixed direction. Today’s AI portfolio expansion at ECR 2026 and Gleamer integration continues that theme but came alongside a -3.51% move, on the weaker side of recent reactions.

Historical AI news shows DeepHealth moving from initial ECR showcases to broader RSNA launches, large real-world studies and payer adoption. The current announcement extends this trajectory by unifying multiple disease-specific AI suites, adding musculoskeletal and X-ray coverage via Gleamer, and emphasizing enterprise-scale orchestration across modalities.

Market Pulse Summary

This announcement highlights DeepHealth’s broadened AI portfolio across breast, chest, neuro, prosta...

Analysis

This announcement highlights DeepHealth’s broadened AI portfolio across breast, chest, neuro, prostate and thyroid imaging, now augmented by the Gleamer acquisition and AI Studio’s 140+ algorithms. Clinical data points, such as a 21% boost in breast cancer detection and 92% neuro sensitivity, underscore performance claims. Historically, AI news has produced mixed price reactions, so investors may track adoption metrics, recurring software revenue and additional clinical outcomes to gauge the long-term impact.

Key Terms

ce-marked, white matter hyperintensity, wmh, flair mri, +2 more

6 terms

ce-marked regulatory

"the newly CE-marked TechLive™ multimodality vendor-agnostic remote image management"

CE-marked indicates a product meets European Union requirements for safety, performance and legal compliance, allowing it to be sold across the European Economic Area. For investors, a CE mark is like a passport or safety stamp — it reduces regulatory and market-entry risk, can speed sales and adoption across many countries, and signals the maker completed required testing and documentation, which can affect revenue forecasts and valuation.

white matter hyperintensity medical

"its white matter hyperintensity (WMH) algorithm, with DeepHealth research presented"

Small bright spots seen on brain MRI that show areas where white matter — the wiring that connects different brain regions — has been damaged or altered, often from aging, blood vessel changes, or other health conditions. Investors care because their presence predicts higher risk of stroke, cognitive decline and disability, which can influence demand for drugs, diagnostics, long‑term care costs and the outcomes of clinical trials, similar to spotting rust on a machine that signals hidden wear and future repair costs.

wmh medical

"its white matter hyperintensity (WMH) algorithm, with DeepHealth research presented"

White matter hyperintensity (WMH) are small bright spots seen on brain MRI scans that reflect areas of reduced blood flow or mild tissue damage often linked to aging, stroke risk, or vascular disease. For investors following healthcare companies, WMH are important because changes in their number or size are used as clinical trial outcomes, influence diagnosis and treatment decisions, and can affect the market potential and regulatory evaluation of therapies aimed at preventing or slowing brain injury—think of them as wear-and-tear patches doctors track to judge whether a treatment is working.

flair mri medical

"consistent anatomical labeling across multiple FLAIR MRI scans — delivering"

FLAIR MRI (fluid-attenuated inversion recovery magnetic resonance imaging) is a brain-scanning technique that suppresses the bright signal from fluid so small abnormalities, like scars, inflammation, or tumors, stand out more clearly—think of dimming background light to see faint stars. Investors watch FLAIR MRI because its diagnostic power influences demand for advanced scanners, affects clinical trial imaging standards, and can drive sales and regulatory choices for medical-imaging firms and hospitals.

auc medical

"multi-reader study, which found applications of the Suite improved radiologists' area under the curve (AUC)"

Area under the curve (AUC) measures the total exposure of the body to a drug over time by calculating the area beneath a plot of drug concentration versus time. For investors, AUC indicates how much of a medicine reaches and stays in the bloodstream, which affects dosing, safety and effectiveness—similar to measuring how much water flows through a pipe over a day rather than just its peak pressure.

vendor-agnostic technical

"TechLive™ multimodality vendor-agnostic remote image management solution, will be showcased"

Vendor-agnostic describes products, services, or strategies designed to work with equipment, software, or suppliers from any provider rather than relying on a single brand. For investors, it signals lower operational risk and greater flexibility because a business can switch partners, avoid costly lock-in, and adapt more easily to better or cheaper options—similar to using a universal charger that fits many devices.

AI-generated analysis. Not financial advice.

DeepHealth is introducing in Europe its cloud-first integrated portfolio combining clinical AI, multi-modality viewing and reporting, which is designed to improve outcomes, efficiency and access to care

VIENNA, March 04, 2026 (GLOBE NEWSWIRE) -- DeepHealth, a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today unveils at ECR 2026 the industry's most comprehensive portfolio of native clinical AI solutions and services across all core imaging modalities — MR, CT, X-ray, Mammography and Ultrasound — and spanning detection, assessment and monitoring, all available on one platform. With this week’s acquisition of Gleamer, DeepHealth further expands its leadership in advancing screening tools into routine imaging and acute diagnostic care, uniquely positioned to deliver the next era of AI-powered health informatics. 

"As European nations scale their screening ambitions and confront rising workload pressures, our integrated portfolio is designed to stage shift disease, empower diagnostic excellence and expand patient access, thereby driving precision care," said Niccolo Stefani, MD, Business Leader Population Health & Clinical AI, DeepHealth.  "These solutions transform imaging pathways, enabling healthcare systems to move from reactive treatment to proactive intervention while addressing the realities of diverse European markets, to improve patient outcomes."  

The Industry’s Most Comprehensive Native Clinical AI Portfolio   
DeepHealth’s expanded European portfolio now delivers a fully integrated, end-to-end suite of modular AI solutions, validated by clinical evidence and proof at scale in real-world settings. Designed to stage-shift disease through earlier detection, the portfolio enhances diagnostic consistency while driving meaningful gains in operational efficiency.  

• Breast Suite.ⁱ A modular solution that integrates AI-powered detection, risk assessment,ⁱⁱ breast density analysis and new mammography analytics based on our recent acquisition of Aquila.  Aquila’s solution complements DeepHealth’s existing AI-powered breast imaging portfolio by adding the ability to measure, monitor and improve image quality across technologists, sites and workflows, thereby strengthening clinical teams and enabling connected, scalable care in high-volume screening environments with the strict compliance standards.  A landmark Nature Health study validated the real-world impact of applications within the Suite, demonstrating a 21% increase in breast cancer detection rate among over 579,000 women.ⁱⁱⁱ  For the millions of women with dense breasts or elevated breast cancer risk, supplemental ultrasound is a critical complement to mammography — and DeepHealth is now extending its Breast Suite to include AI-powered breast ultrasound, building on the strategic acquisition and integration of See-Mode. Moving from detection to proactive care, Breast Suite’s AI-powered risk assessment tool predicts a patient’s near-term risk of developing cancer based only on a mammogram, with 2x greater accuracy than traditional risk models.^ivv  At ECR 2026, DeepHealth will present research^vi showing its AI breast arterial calcifications (BAC)^vii algorithm accurately detects cardiovascular risk indicators directly from routine mammography — extending the Breast Suite's clinical value beyond cancer detection.  
  
  
• Chest Suite: Chest Suite^viii applications automate pulmonary nodule detection, characterization and volumetric quantification with standardized reporting and longitudinal tracking — with the ultimate goal of stage-shifting lung cancer.  Applications of this suite support the NHS England’s Lung Cancer Screening program and France’s CASCADE lung cancer screening study, validating AI's role in population-based lung-cancer screening. DeepHealth will present research at ECR 2026^ixx confirming that AI-assisted nodule detection significantly improves radiologists' diagnostic accuracy, interobserver agreement and read efficiency — with consistent performance across both routine clinical and screening low-dose CT examinations.  
  
• Neuro Suite: Neuro Suite^xi applications automate neuroimaging analysis to enable proactive neurological care, automatically quantifying key brain structures, including the hippocampus, cortical lobes and subcortical regions, to support precise longitudinal tracking and early intervention for neurodegenerative conditions.  Awarded “Best AI in Healthcare 2023” at the Italian Health System Forum, applications within Neuro Suite demonstrated 92% sensitivity in the early identification of hippocampal atrophy associated with mild cognitive disorders and Alzheimer’s disease.^xii  Central to the solution is its white matter hyperintensity (WMH) algorithm, with DeepHealth research presented at ECR 2026^xiii demonstrating expert-level automated quantification and consistent anatomical labeling across multiple FLAIR MRI scans — delivering the granular, reproducible biomarker data that enables meaningful risk stratification and longitudinal assessment at scale.    

• Prostate Suite: Prostate Suite^xiv integrates automated lesion detection and risk classification, intelligent gland segmentation with PSA density calculation and PI-RADS-compliant reporting into one seamless platform, supporting more than nine fusion biopsy systems to eliminate manual data transfer and support radiologists at every critical decision point. Prostate Suite application has been chosen to support TRANSFORM, the U.K.'s largest prostate cancer screening trial in a generation. At ECR, DeepHealth will present a multi-reader study,^xv which found applications of the Suite improved radiologists' area under the curve (AUC) and more than doubled interobserver agreement.
  
  
• Thyroid Suite: Thyroid Suite^xvi is an AI-powered, modular solution that automates nodule detection, characterization, measurements and reporting within existing thyroid ultrasound workflows, building on the acquisition and integration of See-Mode.  Deployment across more than 200 RadNet sites has demonstrated transformative real-world impact: radiologists accepted AI-based measurements and characterization without correction in greater than 94% of cases^xvii and the ability to reduce scan slot time by up to 30%,^xviii thereby expanding clinical capacity. DeepHealth’s ECR 2026 clinical data^xix reinforces this impact, showing that AI assistance significantly reduced interpretation time while improving radiologist accuracy, agreement and consistency in thyroid nodule characterization.  
  
  
• AI Studio: Supporting its integrated Population Health suites, DeepHealth’s AI Studio Suite provides a unified platform to accelerate enterprise-wide AI adoption with confidence.  AI Studio adds more than 140 AI algorithms from over 75 ecosystem partners — alongside DeepHealth’s own clinical AI applications — and seamlessly orchestrates them within the clinical workflow, including the worklist, viewer, reporting modules and workflow engine. The platform enhances automation, streamlines deployment and elevates the viewing and reporting experience.  In parallel, AI Studio delivers comprehensive governance capabilities, including AI validation, continuous monitoring and drift management in production, ensuring consistent performance and the safe, reliable scaling of AI across the healthcare enterprise.  
  
  

“DeepHealth's unified platform has fundamentally changed how we serve our patients,” commented the medical leadership of Emicenter Diagnostic Center in Italy.  “From prostate and lung cancer screening to the assessment of neurodegenerative disease, we now have one cohesive, AI-powered ecosystem that gives our radiologists the clinical confidence to detect disease earlier and the workflow efficiency to do it at scale.”  

Delivering the Next Era of AI-Powered Health Informatics   
With the integration of Gleamer’s solutions into DeepHealth’s established clinical AI suites, the company now offers the most comprehensive radiology AI portfolio in the market adding a significant portfolio in musculoskeletal and X-ray imaging. The combined solutions support screening, detection, interpretation and follow-up across many of the most prevalent cancers, as well as neurodegenerative and musculoskeletal conditions, including trauma and chronic disease.  

DeepHealth's expanded clinical AI portfolio,^xx including its Diagnostic Suite™ cloud-first enterprise image management and interpretation solution, and the newly CE-marked TechLive™ multimodality vendor-agnostic remote image management solution, will be showcased at ECR 2026 at Booth No. 506 | Hall X5.  For more information or to schedule a demonstration, visit www.deephealth.com/ECR.  
  
About DeepHealth   
DeepHealth is a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for RadNet’s Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in breast, chest, musculoskeletal, neuro, prostate and thyroid health. At the heart of DeepHealth’s portfolio is a cloud-native operating system – DeepHealth OS – that unifies data across the clinical and operational workflow. Thousands of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth’s human-centered, intuitive technology aims to push the boundaries of what’s possible in healthcare. Learn more at deephealth.com.  
  
About RadNet, Inc.   
RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of owned and/or operated outpatient imaging centers. RadNet’s imaging center markets include Arizona, California, Delaware, Florida, Indiana, Maryland, New Jersey, New York, Texas and Virginia. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 11,000 team members. Learn more at radnet.com.  
  
Forward-Looking Statements  
This communication contains certain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “possible,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would,” the negative of these words, and similar references to future periods.  Examples of forward-looking statements include statements regarding our technology’s ability to address the compounding challenges facing healthcare systems, including workforce constraints, rising imaging volumes and the need for consistent, high-quality diagnostic pathways; discussions regarding our product features; and statements regarding our recent acquisitions.  Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet’s control.  
  
Forward-looking statements are neither historical facts nor assurances of future performance.  Instead, they are based only on management’s current beliefs, expectations and assumptions regarding the future of RadNet’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet’s control. RadNet’s actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. Neither RadNet, nor any of its directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet’s business and the ability to realize the expected benefits of the acquisition. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of the technology, and (2) the risk of legislative, regulatory, economic, competitive, and technological changes, and other risks and uncertainties described in the “Risk Factors,” “Management’s Discussion and Analysis,” and other sections of our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.  The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere.  Additional information concerning risks, uncertainties and assumptions can be found in RadNet’s filings with the Securities and Exchange Commission (the “SEC”), including the risk factors discussed in RadNet’s most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC.  
  
Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, RadNet does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.  
  
DeepHealth Media Contact  
Andra Axente  
Director of Communications  
+31614440971  
andra.axente@deephealth.com  
  
RadNet Media Contacts   
Jane Mazur   
Senior Vice President, Corporate Communications  
+1 585-355-5978   
jane.mazur@radnet.com   
  
Mark Stolper  
Executive Vice President and Chief Financial Officer  
+1 310-445-2800  

  
References  

ⁱ Breast Suite comprises multiple applications including ProFound Pro, Breast Density, Safeguard Review, Risk Assessment, BAC and DeepHealth Viewer, Mammography Insights and Breast Ultrasound. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. Mammography Insights is manufactured by Aquila, Inc. and distributed by DeepHealth, Inc. Breast Ultrasound is manufactured by See-Mode, Inc. and distributed by DeepHealth, Inc. Any claims made about Breast Suite may reference claims associated with its individual components.
ⁱⁱ CE marked for the EU market. Not yet cleared for use in the US.
ⁱⁱⁱ Louis et al. “Equitable impact of an AI-driven breast cancer screening workflow in real-world US-wide deployment.” Nature Health. Nov 2025.
^iv Eriksson et al. “A risk model for digital breast tomosynthesis to predict breast cancer and guide clinical care.” Science Translational Medicine. May 2022.
^v Eriksson et al. “Identification of Women at High Risk of Breast Cancer Who Need Supplemental Screening.” Radiology. Sep 2020.
^vi Hasegawa, A., Pike, J., Gkanatsios, N., Go, J., Everitt, B., Ge, J., Ren, Y., Ng, A., Kim, J., & Haslam, B., “AI assistant for detection and localization of breast arterial calcifications on FFDM and DBT mammography with potential cardiovascular risk implications,” European Congress of Radiology (ECR) 2026. Poster presentation. March 2026.
^vii In development.
^viii Chest Suite comprises multiple applications, including Veye Lung Nodules, Veye Reporting, DeepHealth Lung AI, DeepHealth Viewer and HealthCCSng.  Veye Lung Nodules and Veye Reporting are manufactured by Aidence B.V. and distributed by DeepHealth, Inc.  Neither Veye Lung Nodules nor Veye Reporting are FDA cleared for distribution in the U.S.  DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. in the U.S.  HealthCCSng is manufactured by Nanox AI, Ltd. and distributed by DeepHealth, Inc.  DeepHealth Lung AI is 510(k) pending.  Any claims made about Chest Suite may reference claims associated with its individual components. Not all products and functions are available in all markets.
^ix Kim, J., Engbersen, M., Mollink, J., Poirot, M., Kurilova, I., Everitt, B., Hasegawa, A., and Haslam, B., “AI-assisted lung nodule detection on computed tomography: effects on diagnostic accuracy, consistency, and efficiency,” European Congress of Radiology (ECR) 2026. Poster presentation. March 2026.
^x Wakelin, E., Mollink, J., Koulakis, M., Engbersen, M., & Haslam, B., “Evaluation of AI Detection of Lung Nodules in Routine Chest CTs Compared to Lung Cancer Screening CTs,” European Congress of Radiology (ECR) 2026. Poster presentation. March 2026.
^xi Neuro Suite comprises multiple applications, including Brain Health, Brain Age and DeepHealth Viewer.  DeepHealth Viewer is manufactured by eRAD, inc. and distributed by DeepHealth.  Any claims made about Neuro Suite may reference claims associated with its individual components.  Not all products and functions are available in all markets.
^xii Preliminary data from the observational study conducted at ASL Roma 2 on 226 geriatric patients starting from February 2023 to date, to investigate early diagnosis of dementia with the use of neuropsychological tests and AI-powered (DeepHealth ND) MRI automated evaluation of brain volumetry.
^xiii Moeskops, P., Mulder, L., Wakelin, E., Ng, A., Kim, J., & Haslam, B., “Automated quantification and localization of white matter hyperintensities in FLAIR MRI to support disease risk stratification and longitudinal assessment,” European Congress of Radiology (ECR) 2026. Poster presentation. March 2026.
^xiv DeepHealth Prostate Suite comprises multiple applications including Quantib Prostate, DeepHealth Prostate AI and DeepHealth Viewer. Quantib Prostate is Manufactured by Quantib BV and distributed by DeepHealth, Inc, in the US. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. DeepHealth Prostate AI is FDA 510(k) pending Any claims made about Prostate Suite may reference claims associated with its individual components.
^xv Everitt, B., Fortunati, V., Kim, J., Tol, J., Ko, A., Kolpa, G., Leufkens, F., & Haslam, B., “Impact of an integrated AI platform on prostate MRI interpretation: a multi-reader study,” European Congress of Radiology (ECR) 2026. Poster presentation. March 2026.
^xvi DeepHealth Thyroid Suite comprises multiple applications, including DeepHealth Viewer and DeepHealth Thyroid AI.  DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth.  DeepHealth Thyroid AI is manufactured as See-Mode Augmented Reporting Tool, Thyroid (SMART-T) by See-Mode and distributed by DeepHealth Inc. Any claims made about Thyroid Suite may reference claims associated with its individual components.  Not all products and functions are available in all markets.
^xvii Results are based on data from 240+ RadNet sites and 22,000 thyroid studies [Data on File].
^xviii Demonstrated up to a 30% reduction in scan slot time. Results from early solution deployment on RadNet sites [Data on File].
^xix Monajemi, S., Louis, L. D., Ng, A., Engin, M., Surendrakumar, S., Parkitny, S., Vo, J., Mohammadzadeh, M., & Haslam, B., “AI assistant improves interpretation efficiency, consistency and accuracy for thyroid ultrasound,” European Congress of Radiology (ECR) 2026. Poster presentation. March 2026.
^xx Not all products are regulatory cleared for use in all markets. Regulatory clearance varies by region and product. Please refer to www.deephealth.com or contact our regulatory affairs team for more information on the specific clearances applicable in your market.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c259eede-a9aa-4878-b943-09d8eb96ab2c

FAQ

What did DeepHealth (RDNT) announce at ECR 2026 on March 4, 2026?

DeepHealth announced a cloud-first integrated clinical AI portfolio and the acquisition of Gleamer to expand X-ray and musculoskeletal AI. According to the company, the launch unifies native AI suites across MR, CT, X-ray, mammography and ultrasound for enterprise use.

How did DeepHealth's Breast Suite perform in real-world studies presented at ECR 2026?

Breast Suite applications showed a 21% increase in breast cancer detection across 579,000 women in real-world data. According to the company, this study validates earlier detection and improved screening performance in high-volume programs.

What clinical evidence supports DeepHealth's Neuro Suite performance at ECR 2026?

Neuro Suite demonstrated 92% sensitivity for early hippocampal atrophy detection associated with mild cognitive disorders. According to the company, the suite enables automated, reproducible longitudinal brain structure quantification for risk stratification.

How widely is DeepHealth's thyroid AI deployed and what operational impact was reported?

Thyroid Suite deployment spans over 200 RadNet sites with AI measurements accepted without correction in >94% of cases. According to the company, AI assistance reduced scan slot time by up to 30%, expanding clinical capacity.

What does DeepHealth's acquisition of Gleamer mean for RDNT shareholders?

The Gleamer acquisition expands DeepHealth's radiology AI coverage into musculoskeletal and X-ray imaging, broadening product reach and screening support. According to the company, the deal augments its comprehensive portfolio showcased at ECR 2026.

What capabilities does DeepHealth's AI Studio provide for enterprise AI adoption?

AI Studio integrates and orchestrates over 140 algorithms from 75 partners into clinical workflows, providing validation, monitoring and drift management. According to the company, this supports enterprise-wide, governed adoption of AI across imaging and reporting systems.